My colleague Yihan Shi and I posted the linked paper showing that all prescription drugs slated for Medicare negotiation and likely to soon be negotiated are making healthy returns on R&D investments. www.brookings.edu/articles/cum...
www.brookings.edu
Richard Frank and Yihan Shi investigate the net sales of drugs selected for the second round of negotiation and future drug selections.
